Mirae Asset Global Etfs Holdings Ltd. Astria Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 30,167 shares of ATXS stock, worth $337,870. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,167Holding current value
$337,870% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
102Shares Held
49.4MCall Options Held
27.6KPut Options Held
29.7K-
Perceptive Advisors LLC New York, NY6.49MShares$72.6 Million1.71% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.04MShares$56.5 Million0.69% of portfolio
-
Vr Adviser, LLC New York, NY3.61MShares$40.4 Million3.6% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$39.8 Million6.42% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$39.4 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $170M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...